McBroom & Associates LLC Trims Holdings in Zoetis Inc. $ZTS

McBroom & Associates LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 19.1% in the third quarter, HoldingsChannel.com reports. The fund owned 28,855 shares of the company’s stock after selling 6,795 shares during the quarter. Zoetis accounts for 2.0% of McBroom & Associates LLC’s portfolio, making the stock its 20th biggest position. McBroom & Associates LLC’s holdings in Zoetis were worth $4,222,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Howland Capital Management LLC grew its holdings in Zoetis by 9.5% during the third quarter. Howland Capital Management LLC now owns 2,341 shares of the company’s stock worth $343,000 after acquiring an additional 204 shares during the period. Evergreen Capital Management LLC increased its holdings in shares of Zoetis by 3.3% in the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after buying an additional 85 shares in the last quarter. Fulcrum Capital LLC lifted its stake in Zoetis by 6.1% during the third quarter. Fulcrum Capital LLC now owns 59,847 shares of the company’s stock valued at $8,757,000 after buying an additional 3,454 shares in the last quarter. Arlington Trust Co LLC boosted its holdings in shares of Zoetis by 15.2% in the third quarter. Arlington Trust Co LLC now owns 1,106 shares of the company’s stock worth $162,000 after buying an additional 146 shares during the period. Finally, First National Advisers LLC raised its position in Zoetis by 0.9% during the third quarter. First National Advisers LLC now owns 30,827 shares of the company’s stock valued at $4,510,000 after buying an additional 272 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.4%

Shares of NYSE ZTS opened at $124.79 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The company’s 50 day simple moving average is $123.21 and its 200 day simple moving average is $139.49. The firm has a market capitalization of $54.99 billion, a P/E ratio of 21.01, a P/E/G ratio of 2.53 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is currently 35.69%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a report on Monday, December 15th. KeyCorp began coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday, December 10th. BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. Finally, Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus price target of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.